ArticleFrontiers in pharmacology2022
Identification of therapeutic targets for osteosarcoma by integrating single-cell RNA sequencing and network pharmacology.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- Functional validation of driver mutation-specific uveal melanoma biomarkers: role of COL9A3 in cancer cell plasticity.The Journal of pathology · 2026Article
- Integration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma.Cancers · 2026Article
- A risk score model based on glycosylation-related genes for predicting radioresistance and prognosis of lung adenocarcinoma.Translational cancer research · 2026Article
- Identification of Key Bioactive Compounds of Medicine-Food Homologous Substances and Their Multi-Target Intervention Effects in Osteosarcoma Treatment.International journal of molecular sciences · 2026Article
- Analysis of the effects of M2 macrophage-derived PDE4C on the prognosis, metastasis and immunotherapy benefit of osteosarcoma.Journal of cellular and molecular medicine · 2024Article
- Immunogenic cell death related mRNAs associated signature to predict immunotherapeutic response in osteosarcoma.Heliyon · 2024Article
- Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer.Frontiers in immunology · 2024Article
- Single-cell RNA sequencing reveals the communications between tumor microenvironment components and tumor metastasis in osteosarcoma.Frontiers in immunology · 2024Article
- Deciphering gastric inflammation-induced tumorigenesis through multi-omics data and AI methods.Cancer biology & medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.